Boston Scientific posted a first‑quarter net profit of $1.34 billion, roughly twice the year‑ago figure, driven by accelerating demand for its cardiology portfolio. Earnings per share rose to 90 cents from 45 cents, while adjusted earnings hit 80 cents, just above FactSet’s 79‑cent consensus.

Revenue climbed 12% to $5.2 billion, edging past the $5.17 billion analyst forecast. Cardiology sales surged 14% to $3.5 billion, reflecting robust global uptake of stents and catheters, while the MedSurg unit contributed $1.7 billion, up 7.8%. Growth was broad‑based, with Latin America and Canada posting a 19% jump.

Despite the strong top‑line, the company trimmed its full‑year adjusted earnings growth target, citing uncertainty around cost pressures and competitive pricing. Investors will reassess valuation metrics as the revised outlook narrows the upside potential that had buoyed the stock earlier in the year.

The results underscore Boston Scientific’s resilience in a crowded medical‑device market, but the earnings downgrade signals that analysts will weigh margin dynamics as closely as volume growth when forecasting future performance.